Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Rhodococcus equi

  • Author: Indira Kedlaya, MD; Chief Editor: Burke A Cunha, MD  more...
 
Updated: Apr 13, 2015
 

Background

Rhodococcus equi primarily causes zoonotic infections in grazing animals, mainly horses and foals.[1, 2] Although R equi rarely infects immunocompetent humans, it is emerging as an important pathogen in immunocompromised persons.

R equi is a facultative, intracellular, nonmotile, non–spore-forming, gram-positive coccobacillus (an organism that has the ability to exist as a coccus or bacillus or intermediate form). Called Rhodococcus because of its ability to form a red (salmon-colored) pigment, R equi can be weakly acid-fast and bears a similarity to diphtheroids. R equi was previously called Corynebacterium equi and is currently grouped with the aerobic actinomycetes. Of the 40 genera in the actinomycetes group, the Rhodococcus genus is placed among the nocardioform bacteria, along with the genera Mycobacterium, Nocardia, Gordonia, Tsukamurella, and Corynebacterium.

R equi was first isolated in 1923 from foals as Corynebacterium equi. R equi infection in a human was first reported in 1967 in a 29-year-old man with plasma cell hepatitis receiving immunosuppressant medications. Since then, R equi has become an important opportunistic pathogen in immunocompromised patients, especially those with acquired immunodeficiency syndrome (AIDS). R equi infection is associated with significant mortality. The organism can be difficult to eradicate, making treatment challenging at times. Increased awareness of R equi infection may help with early diagnosis and timely treatment. Treatment may require prolonged combination antibiotic therapy, sometimes in combination with surgical therapy.

Next

Pathophysiology

Necrotizing pneumonia is the most common manifestation of R equi infection . Extrapulmonary R equi infections have included wound infection, subcutaneous abscess, brain abscess, thyroid abscess, retroperitoneal abscess, peritonitis, meningitis, pericarditis, osteomyelitis, endophthalmitis, lymphadenitis, lymphangitis, septic arthritis, osteitis, bloody diarrhea, and fever of unknown origin, among others. Bacteremia and dissemination of infection follow from the primary infection site, which is usually the lung.

The primary source of infection may also be from the alimentary tract. This hypothesis arises from a few observations. First, in patients infected with human immunodeficiency virus (HIV), R equi has been isolated from the stool, with or without evidence of pneumonia. Second, R equi frequently colonizes the gastrointestinal tract in grazing animals. In addition, Verville and colleagues (1994) described an incidental finding of R equi mesenteric lymphadenitis in a woman undergoing laparotomy for cholelithiasis.[3] Hence, the possibility of asymptomatic carriage in the gastrointestinal tract in human beings, similar to grazing animals, has been proposed. Third, a case of cervical lymphadenitis has been attributed to a history of sucking raw carrots.

In experimental and natural animal infections, R equi acts as an intracellular bacterium, which survives within macrophages and eventually destroys them. Experimental data suggest that R equi is capable of inhibiting oxidative bactericidal functions of polymorphonuclear cells. Electron microscopy of R equi in equine macrophages demonstrates that the organisms appear to avoid being killed by interfering with phagosome-lysosome fusion.

Pathogenesis

Most of the information about the pathogenesis of R equi infections is derived from animal isolates. However, the infection in humans seems to differ from that in foals. Makrai et al demonstrated that a 15- to 17-kd virulence-associated protein antigen (VapA), which is highly virulent, may mediate about 88% of the isolates from foals.[4] Nearly all isolates from pigs are of 20-kd virulence-associated protein antigen (VapB) origin, which is of intermediate virulence. In human beings, only about 20-25% of isolates have been reported to express VapA. However, in a study performed by Takai et al in Thailand, about 75% of human isolates expressed VapB, and 25% were avirulent. Most of these patients were infected with HIV.[5]

The expression of VapB is known to vary by geographic location. These differences between human and animal R equi infections are important since most of the investigation has involved VapA isolates. Hence, the conclusion drawn from animal models may not be entirely applicable to the pathogenesis of R equi infections in humans.

Previous
Next

Epidemiology

Frequency

United States

R equi infections have been reported in at least 28 states.

International

R equi infections have been reported on 5 continents. Thus far, a few hundred cases of R equi infections in immunocompromised persons have been reported in the literature. At least 19 cases of R equi infection have been described in immunocompetent patients.

Mortality/Morbidity

Morbidity is related to complications and chronicity of the infection. Numerous complications are related to R equi infections. R equi pneumonia may be complicated by the following:

  • Abscess
  • Empyema
  • Pleural effusion
  • Hemoptysis
  • Direct chest wall involvement
  • Pneumothorax

Pericardial tamponade may result from purulent pericarditis. Bacteremia leading to overwhelming sepsis has been reported, more often in immunocompromised patients. In a review by Verville et al (1994), about 47% of patients infected with HIV and 17% of patients with non–HIV-associated immunocompromised conditions had chronic R equi infection.[3] Relapses are also common after discontinuation of antibiotics. An important site of extrapulmonary relapse is the central nervous system.

R equi infections carry an overall mortality rate of about 25%. In 2 different reports, by Cornish et al[6] (1999) and by Harvey and Sunstrum[7] (1991), the mortality rate was 50-55% in patients infected with HIV and 20-25% in patients with non–HIV-associated immunocompromised conditions. In contrast, the mortality rate is only about 11% in immunocompetent patients.

Since the advent of highly active antiretroviral therapy (HAART) therapy, mortality rates in HIV-infected patients have decreased. Torres-Tortosa et al conducted a multicenter observation of 67 HIV-infected patients in Spain.[8] The mortality rate related to R equi was 34.3%. In a univariate analysis in the same study, factors associated with worse prognosis included multilobar involvement, absence of HAART, and inappropriate antibiotic therapy. In multivariate analysis, absence of HAART was the only factor independently associated with R equi –related mortality. While the mortality rate is lower in immunocompetent patients, it is still significant. Lower mortality rates in this subgroup of patients may be due to the fact that localized infections represent about 50% of the cases reported. The high mortality rates associated with R equi infections are due to several factors.

R equi may be misidentified as diphtheroids, Mycobacterium species, or Nocardia species among both immunocompetent and immunocompromised populations.

Patients with R equi infection may receive inappropriate initial antibiotic therapy because of misdiagnosis. R equi pneumonia does not respond to standard empirical treatment with beta-lactams (other than imipenem and meropenem) and tetracyclines. On the other hand, some cases of R equi pneumonia may be susceptible to macrolides and the newer quinolones.

Simultaneous opportunistic infections are common, especially in patients infected with HIV. In this subgroup of patients, the mortality rate directly attributed to R equi infection alone may be less. Capdevila et al (1997) reported on a series of patients infected with HIV who had R equi pneumonia; in this group of patients, the mortality rate directly attributed to R equi infection was only 15.4%.[9] In another review of R equi infections in patients infected with HIV, 4 of 12 patients died of R equi infection, while 3 deaths were due to opportunistic infections.

Race

R equi infections have no reported racial predilection.

Sex

In all R equi infections, the male-to-female ratio is about 3:1. The reason for this is not clear; however, among immunocompromised patients, the predilection in males may be explained by the higher prevalence of HIV infection among males.

Age

R equi infections have been described in all age groups, from infants to elderly persons. Separate reviews have found a mean age of infection of 34-38 years.

Infection in children

R equi infections in children differ from those in adults. Immunocompromising conditions, including hematopoietic malignancies, immunosuppression associated with chemotherapy, and HIV infection, account for only about one third of reported R equi infections in children. Pediatric R equi infections account for approximately one third of all cases among immunocompetent individuals, perhaps because of the increased prevalence of trauma among children, predisposing them to localized R equi wound infections .R equi infections in immunocompetent children carry an extremely favorable prognosis.

Previous
 
 
Contributor Information and Disclosures
Author

Indira Kedlaya, MD Consulting Staff, Sunshine Medical Group, PLLC

Indira Kedlaya, MD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Michael Ing, MD Chief, Section of Infectious Disease, JL Pettis Memorial Veterans Affairs Medical Center; Associate Professor, Infectious Disease Section, Department of Internal Medicine, Loma Linda University School of Medicine

Michael Ing, MD is a member of the following medical societies: American Society for Microbiology, Alpha Omega Alpha, Royal Society of Tropical Medicine and Hygiene, HIV Medicine Association, American Academy of HIV Medicine, American College of Physicians-American Society of Internal Medicine, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, International AIDS Society, Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Aaron Glatt, MD Chief Administrative Officer, Executive Vice President, Mercy Medical Center, Catholic Health Services of Long Island

Aaron Glatt, MD is a member of the following medical societies: American College of Chest Physicians, American Association for Physician Leadership, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Infectious Diseases Society of America, International AIDS Society, Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Additional Contributors

Larry I Lutwick, MD Professor of Medicine, State University of New York Downstate Medical School; Director, Infectious Diseases, Veterans Affairs New York Harbor Health Care System, Brooklyn Campus

Larry I Lutwick, MD is a member of the following medical societies: American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

References
  1. Giguère S, Cohen ND, Keith Chaffin M, Hines SA, Hondalus MK, Prescott JF, et al. Rhodococcus equi: Clinical Manifestations, Virulence, and Immunity. J Vet Intern Med. 2011 Nov. 25(6):1221-30. [Medline].

  2. Giguère S, Cohen ND, Keith Chaffin M, Slovis NM, Hondalus MK, Hines SA, et al. Diagnosis, Treatment, Control, and Prevention of Infections Caused by Rhodococcus equi in Foals. J Vet Intern Med. 2011 Nov. 25(6):1209-20. [Medline].

  3. Verville TD, Huycke MM, Greenfield RA, et al. Rhodococcus equi infections of humans. 12 cases and a review of the literature. Medicine (Baltimore). 1994 May. 73(3):119-32. [Medline].

  4. Makrai L, Takai S, Tamura M, et al. Characterization of virulence plasmid types in Rhodococcus equi isolates from foals, pigs, humans and soil in Hungary. Vet Microbiol. 2002 Sep 24. 88(4):377-84. [Medline].

  5. Takai S, Tharavichitkul P, Takarn P, et al. Molecular epidemiology of Rhodococcus equi of intermediate virulence isolated from patients with and without acquired immune deficiency syndrome in Chiang Mai, Thailand. J Infect Dis. 2003 Dec 1. 188(11):1717-23. [Medline].

  6. Cornish N, Washington JA. Rhodococcus equi infections: clinical features and laboratory diagnosis. Curr Clin Top Infect Dis. 1999. 19:198-215. [Medline].

  7. Harvey RL, Sunstrum JC. Rhodococcus equi infection in patients with and without human immunodeficiency virus infection. Rev Infect Dis. 1991 Jan-Feb. 13(1):139-45. [Medline].

  8. Torres-Tortosa M, Arrizabalaga J, Villanueva JL, Galvez J, Leyes M, Valencia ME. Prognosis and clinical evaluation of infection caused by Rhodococcus equi in HIV-infected patients: a multicenter study of 67 cases. Chest. 2003 Jun. 123(6):1970-6. [Medline].

  9. Capdevila JA, Bujan S, Gavalda J, et al. Rhodococcus equi pneumonia in patients infected with the human immunodeficiency virus. Report of 2 cases and review of the literature. Scand J Infect Dis. 1997. 29(6):535-41. [Medline].

  10. Talanin NY, Donabedian H, Kaw M, et al. Colonic polyps and disseminated infection associated with Rhodococcus equi in a patient with AIDS. Clin Infect Dis. 1998 May. 26(5):1241-2. [Medline].

  11. Donisi A, Suardi MG, Casari S, et al. Rhodococcus equi infection in HIV-infected patients. AIDS. 1996 Apr. 10(4):359-62. [Medline].

  12. Menon V, Gottlieb T, Gallagher M, Cheong EL. Persistent Rhodococcus equi infection in a renal transplant patient: case report and review of the literature. Transpl Infect Dis. 2012 Dec. 14(6):E126-33. [Medline].

  13. Kedlaya I, Ing MB, Wong SS. Rhodococcus equi infections in immunocompetent hosts: case report and review. Clin Infect Dis. 2001 Feb 1. 32(3):E39-46. [Medline].

  14. Nath SR, Mathew AP, Mohan A, R AK. Rhodococcus equi granulomatous mastitis in an immuno-competent patient - A case report. J Med Microbiol. 2013 May 22. [Medline].

  15. Munoz P, Palomo J, Guinea J, et al. Relapsing Rhodococcus equi infection in a heart transplant recipient successfully treated with long-term linezolid. Diagn Microbiol Infect Dis. 2008 Feb. 60(2):197-9. [Medline].

  16. Scotton PG, Tonon E, Giobbia M, et al. Rhodococcus equi nosocomial meningitis cured by levofloxacin and shunt removal. Clin Infect Dis. 2000 Jan. 30(1):223-4. [Medline].

  17. Gabriels P, Joosen H, Put E, et al. Recurrent Rhodococcus equi infection with fatal outcome in an immunocompetent patient. Eur J Clin Microbiol Infect Dis. 2006 Jan. 25(1):46-8. [Medline].

  18. Giguère S, Jacks S, Roberts GD, et al. Retrospective comparison of azithromycin, clarithromycin, and erythromycin for the treatment of foals with Rhodococcus equi pneumonia. J Vet Intern Med. 2004 Jul-Aug. 18(4):568-73. [Medline].

  19. Bouchou K, Cathebras P, Dumollard JM, et al. Chronic osteitis due to Rhodococcus equi in an immunocompetent patient. Clin Infect Dis. 1995 Mar. 20(3):718-20. [Medline].

  20. Corne P, Rajeebally I, Jonquet O. Rhodococcus equi brain abscess in an immunocompetent patient. Scand J Infect Dis. 2002. 34(4):300-2. [Medline].

  21. Cunha BA. Antibiotic Essentials. Physicians Press: Royal Oak, Mich; 2005.

  22. Cunha BA. Rhodococcus equi Pneumonia in AIDS Patient - A Commentary. Infect Dis Clin Pract. 1994. 3:119-121.

  23. Drancourt M, Bonnet E, Gallais H, et al. Rhodococcus equi infection in patients with AIDS. J Infect. 1992 Mar. 24(2):123-31. [Medline].

  24. Ebersole LL, Paturzo JL. Endophthalmitis caused by Rhodococcus equi Prescott serotype 4. J Clin Microbiol. 1988 Jun. 26(6):1221-2. [Medline].

  25. Fierer J, Wolf P, Seed L, et al. Non-pulmonary Rhodococcus equi infections in patients with acquired immune deficiency syndrome (AIDS). J Clin Pathol. 1987 May. 40(5):556-8. [Medline].

  26. Germain. A propos d'une observation d'infection humaine a' corynebacterium equi. Med Mal Infect. 1975. 5:294-97.

  27. Hillman D, Garretson B, Fiscella R. Rhodococcus equi endophthalmitis. Case report. Arch Ophthalmol. 1989 Jan. 107(1):20. [Medline].

  28. Jacks SS, Giguere S, Nguyen A. In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials. Antimicrob Agents Chemother. 2003 May. 47(5):1742-5. [Medline].

  29. Johnson DH, Cunha BA. Rhodococcus equi pneumonia. Semin Respir Infect. 1997 Mar. 12(1):57-60. [Medline].

  30. Kwon KY, Colby TV. Rhodococcus equi pneumonia and pulmonary malakoplakia in acquired immunodeficiency syndrome. Pathologic features. Arch Pathol Lab Med. 1994 Jul. 118(7):744-8. [Medline].

  31. Lasky JA, Pulkingham N, Powers MA, et al. Rhodococcus equi causing human pulmonary infection: review of 29 cases. South Med J. 1991 Oct. 84(10):1217-20. [Medline].

  32. Legras A, Lemmens B, Dequin PF, et al. Tamponade due to Rhodococcus equi in acquired immunodeficiency syndrome. Chest. 1994 Oct. 106(4):1278-9. [Medline].

  33. Linares MJ, Lopez-Encuentra A, Perea S. Chronic pneumonia caused by Rhodococcus equi in a patient without impaired immunity. Eur Respir J. 1997 Jan. 10(1):248-50. [Medline].

  34. Moyer DV, Bayer AS. Progressive pulmonary infiltrates and positive blood cultures for weakly acid-fast, gram-positive rods in a 76-year-old woman. Chest. 1993 Jul. 104(1):259-61. [Medline].

  35. Munoz P, Burillo A, Palomo J, et al. Rhodococcus equi infection in transplant recipients: case report and review of the literature. Transplantation. 1998 Feb 15. 65(3):449-53. [Medline].

  36. Muntaner L, Leyes M, Payeras A, et al. Radiologic features of Rhodococcus equi pneumonia in AIDS. Eur J Radiol. 1997 Jan. 24(1):66-70. [Medline].

  37. Nordmann P, Kerestedjian JJ, Ronco E. Therapy of Rhodococcus equi disseminated infections in nude mice. Antimicrob Agents Chemother. 1992 Jun. 36(6):1244-8. [Medline].

  38. Nordmann P, Nicolas MH, Gutmann L. Penicillin-binding proteins of Rhodococcus equi: potential role in resistance to imipenem. Antimicrob Agents Chemother. 1993 Jul. 37(7):1406-9. [Medline].

  39. Nordmann P, Ronco E. In-vitro antimicrobial susceptibility of Rhodococcus equi. J Antimicrob Chemother. 1992 Apr. 29(4):383-93. [Medline].

  40. Schilz RJ, Kavuru MS, Hall G, et al. Spontaneous resolution of rhodococcal pulmonary infection in a liver transplant recipient. South Med J. 1997 Aug. 90(8):851-4. [Medline].

  41. Scott MA, Graham BS, Verrall R, et al. Rhodococcus equi--an increasingly recognized opportunistic pathogen. Report of 12 cases and review of 65 cases in the literature. Am J Clin Pathol. 1995 May. 103(5):649-55. [Medline].

  42. Sigler E, Miskin A, Shtlarid M, et al. Fever of unknown origin and anemia with Rhodococcus equi infection in an immunocompetent patient. Am J Med. 1998 May. 104(5):510. [Medline].

  43. Sladek GG, Frame JN. Rhodococcus equi causing bacteremia in an adult with acute leukemia. South Med J. 1993 Feb. 86(2):244-6. [Medline].

  44. Takai S, Fukunaga N, Ochiai S, et al. Identification of intermediately virulent Rhodococcus equi isolates from pigs. J Clin Microbiol. 1996 Apr. 34(4):1034-7. [Medline].

  45. Takai S, Sasaki Y, Ikeda T, et al. Virulence of Rhodococcus equi isolates from patients with and without AIDS. J Clin Microbiol. 1994 Feb. 32(2):457-60. [Medline].

  46. Thomsen F, Henriques R, Magnusson M. Corynebacterium equi Magnusson isolated from a tuberculoid lesion in a child with adenitis colli. Dan Med Bull. 1968 May. 15(5):135-8. [Medline].

  47. Tunger A, Ozkan F, Vardar F, et al. Purulent meningitis due to Rhodococcus equi. A case of posttraumatic infection. APMIS. 1997 Sep. 105(9):705-7. [Medline].

  48. Vladusic I, Krajinovic V, Begovac J. [Long term survival after Rhodococcus equi pneumonia in a patient with human immunodeficiency virus infection in the era of highly active antiretroviral therapy: case report and review]. Acta Med Croatica. 2006 Jun. 60(3):259-63. [Medline].

  49. Walsh RD, Cunha BA. Rhodococcus equi: fatal pneumonia in a patient without AIDS. Heart Lung. 1994 Nov-Dec. 23(6):519-20. [Medline].

  50. Weinstock DM, Brown AE. Rhodococcus equi: an emerging pathogen. Clin Infect Dis. 2002 May 15. 34(10):1379-85. [Medline].

 
Previous
Next
 
Chest radiograph of a patient with Rhodococcus equi infection showing multiple nodular infiltrates.
Chest radiograph of a patient with Rhodococcus equi infection demonstrating cavitation of pulmonary nodules.
Chest CT scan of a patient with Rhodococcus equi infection demonstrating nodular infiltrates.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.